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doi:10.1016/j.ejvs.2008.03.018Abstract Introduction: Two main treatments exist for the repair of abdominal aortic aneu-
rysm (AAA). Open surgical repair has been the standard treatment, but more recently endovas-
cular aneurysm repair (EVAR) has been introduced as a less invasive technique. To compare the
long-term outcomes of these, utility outcomes have been suggested to be relevant.
Objective: to review studies comparing the utility outcomes of open repair and EVAR
treatment for AAA.
Design: database search with strict inclusion and exclusion criteria.
Materials and Methods: The search was performed in PubMed and EMBASE covering terms
relating to AAA and utility. Studies were analysed qualitatively.
Results: 10 studies of AAA met the review criteria. The comparative utility scores for the
different treatments varied considerably between studies. A Canadian cohort study estimated
EVAR as more favorable than open repair, while randomised controlled trials reported lower
utilities with EVAR, except for one month postesurgery in the EVAR 1 trial. Furthermore, after
screening for AAA, patients testing positive gave similar QoL-5D scores, but worse visual ana-
logue scores than those testing negative.UBC Health Care Analytics, 20 Bloomsbury Square, London WC1A 2NS, UK. Tel.: þ44 20 7299 4550;
nitedbiosource.com (N. Muszbek).
lsevier Ltd on behalf of European Society for Vascular Surgery.
284 N. Muszbek et al.Conclusion: There were few studies calculating utilities in AAA, with inconsistent findings. The
limited reporting of data prevents in-depth analysis to explain the differences.
ª 2008 Published by Elsevier Ltd on behalf of European Society for Vascular Surgery.Introduction
The primary goal of surgical treatment of abdominal aortic
aneurysms (AAA) is the prevention of death from rupture.
Open surgical repair (OR) of AAA is considered to be the
established treatment, but in recent years has been
compared with endovascular aneurysm repair (EVAR).1e3
Data from the randomised controlled trials demonstrated
that EVAR had a lower immediate mortality than open
surgery and conferred an advantage in aneurysm related
mortality up to 4 years follow-up. The trials also demon-
strated that the endovascular technique was more expen-
sive and had a significant number of complications in the
post-operative period.
The EVAR and Dutch Randomised Endovascular Aneurysm
Management (DREAM) trials included patient utility assess-
ments. Utilities for a given health state represent the
preference that individuals have for this health state.4 Util-
ities can be conceptualized as a single summary measure of
health-related quality of life (HRQL) with the anchors of
one corresponding to perfect health and zero corresponding
to death.5,6 Utilities are usually used to estimate quality-
adjusted life years (QALYs), providing a generic health-
related outcome measure for comparison of different
treatments for different patient groups. QALYs, by using
the utility data, take into account not only the mortality,
but also the quality of life of patients. In chronic disease
states, where the quality of life of the patient is impaired
for a prolonged period of time, incorporating utilities into
the economic evaluation can significantly influence the
cost-effectiveness of the intervention. The value of utility
assessments in asymptomatic diseases is less well recog-
nized. However, the recognition of the importance of
quality of life, led to utility data being essential for
economic submissions to reimbursement authorities in
many countries. It is therefore important that any cost-
effectiveness analysis of EVAR includes utility data, as
these data are likely to play a role in any nationally
sponsored health technology assessment.
However utility results from randomised controlled trials
(RCTs) are not reported consistently and appear to lead to
different conclusions. To attempt to understand the differ-
ences and to locate any alternative source of utilities for
the different procedures and all possible health states in
AAA, the available literature on AAA was reviewed.Materials and Methods
An extensive search was performed in MEDLINE and EMBASE,
to capture all published studies incorporating utility and
general quality-of-life measures for abdominal aortic aneu-
rysm. The same search strategy was utilised for alldatabases. Search terms covered the therapeutic area
(AAA) and quality-of-life/utility terms (quality-of-life, util-
ity, patient reported outcomes, quality adjusted life-years,
QALY*, Euroqol, EQ-5D). The limits were human studies and
publication from 1995 onwards, with abstract. The term
‘aneurysm’ had to be found in either the title or the abstract.
Available technology appraisals were also searched. Studies
had to meet all the following inclusion criteria, agreed by
reviewers N.M and J.H, to be included in the review:
 Study in AAA
 Includes original study of utilities
The exclusion criteria were the following:
 Patient population analysed was not greater than ten
 Review articles
 Editorials, letters and practice guidelines
No exclusion criteria were set regarding the length of
follow-up. The most common cause for exclusion was the
study being a review article or the use of disease specific
quality-of-life measures only.
The studies were analysed according to study design,
patient population, comparators, time horizon, outcomes
measures used, the source of utilities and utility and
general quality-of-life results. In addition the limitations
of the studies were explored.
Utility measurement
Utility measures can be obtained from clinical studies
indirectly using instruments, such as EQ-5D or the Rosser
Index, the results of which can be transformed into index
utility scores, or directly with the help of methods, such as
the visual analogue scale (VAS). The usual scale for utilities
has 0.0 for death and 1.0 for perfect health.7
The most commonly used utility measure, also used by
the 3 RCTs is the EQ-5D supplemented by VAS.Results
General findings
Using the above search strategy 242 articles were identi-
fied. After reviewing the abstracts to apply the inclusion
and exclusion criteria, the number of studies was reduced
to 38 articles on aneurysm and one technology appraisal
prepared for the Ontario Ministry of Health & Long-term
Care, for which both the interim8 and the final report were
available,9 as it included an original study of utilities (from
this point referred to as the Ontario study).
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including cerebral and thoracic aneurysms. However, the
studies focusing on AAA (25 studies in total1e3,8e29) were
only of interest in this review. The majority of studies
were conducted in the US and Europe.
Only nine of the articles reported utility estimates.1e3,8,
9,11e15 All of the published studies were found in clinical
journals.
Utilities were calculated with the help of EQ-5D in most
cases.1e3,8,9,11e13,15 Of the studies reporting EQ-5D esti-
mates, four were RCTs comparing EVAR and OR,1e3 or
screening with no screening11; two were prospective cohort
studies assessing OR alone or compared with EVAR8,9,14; one
was a case-control study in screening,15 and one a cross-
sectional study after surgery12 (Table 1).
Apart from the different aims of the studies, and thus
the different comparators, a number of factors prevent
comparison across the studies:
 Although Lottman et al.13 estimated utilities with EQ-
5D, they did not report the EQ-5D index scores, only
the percentage of patients with the different levels of
problem in each of the dimensions and the visual
analogue scores.
 In the DREAM trial,3 the effect-size was published i.e.
the difference in mean scores at the baseline and after
the surgery divided by the standard deviation of the
baseline score.
 In the Ontario study, Bowen et al. reported the detailed
utility data only after adjusting it to the same baseline
value for both OR and EVAR.8 The final report includedTable 1 Utility studies in AAA
Reference,
Country
Type of data
collection
Patient
population
MASS,11 UK Prospective
RCT
men aged 65e74
Ontario study,8,9
Canada
Prospective
Cohort
patients with
AAA> 5.5 cm, age 57e9
male 78e83%
EVAR trial 2.1 UK Prospective
RCT
unfit for OR, aged 60
years, AAA 5.5 cm
EVAR trial 1.2 UK Prospective
RCT
aged 60 years, AAA
 5.5 cm
Laukontaus et al.12,
Finland
Cross
sectional
patient underwent
surgery for ruptured AA
mean age 72, male 92%
Lottman et al.13,
Netherlands
Prospective
RCT
eligible for both OR and
mean age 69, male 72%
mean aneurysm 52 and
Perkins et al.14, UK Prospective
Cohort
patients after OR, medi
age 74, male 85%
DREAM trial,3
Netherlands
Prospective
RCT
eligible for both OR and
mean age 70, male 92%
aneurysms 5.0 cm
Spencer et al.15,
Australia
Prospective
Case-control
men aged 65e83, with s
AAA (30e49 mm)only the twelve month values, without adjusting to
baseline.9
 Perkins et al.14 used different instruments to calculate
utilities (Rosser index), so the results were not compa-
rable to the ones generated with the help of EQ-5D
 Laukontaus et al.12 analyzed open surgery only
 The Multicentre Aneurysm Screening Study (MASS)
trial.11 focused on screening
 Patient populations were different in terms of size of
AAA, general fitness level for surgery, patient age, etc.
Most of the 10 studies assessing utility, also explored
quality of life with other instruments. However these in-
struments, such as the most common general quality of life
instrument, SF-36, employed in seven studies,1e3,8,9,13e15 do
not provide utility values.
Thus, although utility data were available for the first 12
months after surgery or screening, usually in 3 to 6 monthly
intervals (Table 2), the quantitative synthesis of the results
is not possible due to the variation in patient population,
comparators, type of utility measurements and reporting.Utility results in EVAR versus open repair
From the 10 studies, only four reported EQ-5D values for
EVAR (Table 3). Comparative utility data were given for
patients eligible for both OR and EVAR, with aneurysms at
least 5.0e5.5 cm in diameter,1e3,8,9 and for patients unfit
for OR1 at preoperative stage, and at 3 weeks, 6 weeks,
1, 3, 6, 9 and 12 months after the surgery. These studiesPatient
number
Health technology used Follow-up
(months)
no data screening
(after surgery or
surveillance)
12
3,
314 OR or EVAR 12
338 EVAR or no intervention 12e24
1082 OR or EVAR 12e24
A,
94 surgery n.a.
EVAR,
,
56 mm
57 OR or EVAR 3
an 59 OR 6
EVAR,
with
153 OR or EVAR 12
mall 498 screening n.a.
Table 2 Availability of utility data at different time points
Preoperative 3
weeks
1
month
6
weeks
3
months
6
months
9
months
12
months
Ontario study8, a
Ontario study.9
EVAR 12
EVAR 21
MASS11
Perkins et al.14
DREAM3
Spencer et al.15
a adjusted for baseline.
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formats (effect sizes3 and adjusted values8), and different
patient populations (patients unfit for OR in EVAR 2 result-
ing in lower values).
In the Ontario study,8,9 although the scores were similar
to the EVAR 1 trial results2 at one month after the surgery,
they were significantly higher from 3 months onwards.
However, the area under the curve estimation of the utility
for the full 12 months adjusted to baseline differences
produces the value (0.843) which was closer to the 12
month result of the EVAR 1 trial.2,8 The results from the
DREAM trial3 were not comparable as only the changes in
scores are given, and the baseline was not reported. Simi-
larly to EVAR, OR data was available from four studies but
they were not comparable due to different methodology,14
and different reporting formats.3,8,9
With the exception of the study by Perkins et al.,14 all
studies demonstrated an initial dip in utilities due to the
invasive nature of the intervention, but with different
levels of improvement after that.
In the Ontario8,9 and EVAR 1 study,2 although the results
were similar at one year post surgery, the Ontario model
used lower estimates for 1 and 3 months, and higher esti-
mates after that, i.e. in the Ontario study patients had
worse quality of life immediately after the surgery, but
after one year it was better than before surgery. In theTable 3 Utility results for EVAR
Ontario study8, a EVAR12 D
EVAR OR EVAR OR E
preoperative 0.71b 0.71b 0.75 0.74 B
3 weeks 
1 month 0.70 0.56 0.73 0.67
6 weeks 
3 months 0.83 0.67 0.71 0.73
6 months 0.85 0.77 
9 months 0.86 0.82
12 months 0.91 0.91 0.74 0.75 
a adjusted for baseline.
b assumed.
c effect sizes.case of OR, the area under the curve estimation of the util-
ity for the full 12 months, adjusted to baseline differences
(0.777), was even closer to the 12 months result of the EVAR
1 trial,2 than in the case of EVAR. The values calculated by
Perkins et al.14 were higher throughout the study period,
however instead of EQ-5D, the Rosser index was employed
to estimate the utilities. (Table 3)
The relationship between utilities of EVAR and OR varied
from study to study. Whilst the DREAM study3 found a trend
of lower quality of life with EVAR, which was significant at 6
and 12 months, in EVAR 12 open repair had a significantly
lower utility only one month postesurgery. This latter
difference cancelled out, and at the end of one year there
was no difference between the two procedures. At the
same time the Ontario study showed higher estimates for
EVAR throughout the whole year after surgery.9 This might
be due to the Ontario study accounting for major non-EVAR
related complications, such as stroke, congestive heart fail-
ure (CHF), myocardial infarction (MI) and renal failure,
separately.
Although there were studies available comparing the
utilities with OR and EVAR, they came to different
conclusions regarding the relative efficacy of EVAR. In
depth research into the cause of these differences was
prevented by the aforementioned incomparability of the
studies.REAM3, c EVAR 21 Perkins
et al.14
VAR OR EVAR No
intervention
OR
aseline Baseline 0.58 0.63 0.972
0.6 0.5
0.57 0.56
0.3 0.1 0.976
0.0 0.2 0.64 0.60 0.98
0.2 0.3 0.98
0.1 0.5 0.65 0.60
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Utilities for open surgery, of bigger or rapidly expanding
aneurysms and surveillance for smaller aneurysms, were
calculated in the MASS study.11 Utility scores were similar for
both groups preoperatively (0.81), but by 3 and 12 months
quality of life was marginally higher with surgery. Spencer
et al.15 assessed patients with and without AAA after screen-
ing; however they found no significant difference in utility
scores. The utility value for patients undergoing surgery for
ruptured aneurysm was calculated by Laukontaus et al.12
however due to the acute nature of this life threatening con-
dition there was no pre-operative evaluation done. (Table 4)
Utility results with visual analogue scale (VAS)
Utilities plus VAS scores were assessed in 6 studies1,2,
11e13,15 However the 2 EVAR trials did not report the VAS
findings.1,2
Lottman et al.13 estimated VAS for EVAR and OR pre-
operatively, and 1 and 3 months post-operatively in a small
(nZ 76) patient population. The baseline scores were
different for EVAR and OR (67 18 and 61 17 respec-
tively), and they changed only marginally during the study
(68 14 and 61 16 at 1 months, 67 18 and 61 17 at 3
months respectively).
In the MASS trial,11 after screening for AAA, patients’
quality-of-life score was worse with VAS compared with
EQ-5D (76 versus 80). This VAS score improved only in the
case of surgery 3 months post operation (90 for surgery,
77 for surveillance), and decreased by the end of one
year, although this was still not as low as for surveillance
(81 for surgery, 76 for surveillance).11 In another screening
program,15 although there were no significant differences
between men before and after screening, either with
normal abdominal aorta or with AAA, significantly less
men with AAA were likely to have scores 80 than without
AAA (OR: 0.5, 95% CI: 0.3e0.9). The VAS for patients under-
going surgery for ruptured aneurysm was 61.12
Discussion
In the field of AAA treatment few studies were found which
reported utility estimates, with most using the EQ-5D indexTable 4 Additional utilities relating to AAA
Study Patient
Population
Utility
Scores
MASS11 After surgery for bigger or
rapidly expanding aneurysms
0.85
After surveillance for smaller
aneurysms
0.83
Spencer et al. Patients with AAA after
screening before surgery
0.83
Patients without AAA after
screening
0.80
Laukontaus et al. Patients undergoing surgery
for ruptured aneurysm
0.685score. Themain studieswere three randomized trials (EVAR 1
and 2,1,2 DREAM3) and the Ontario cohort study.8,9 The scores
were usually given at more frequent intervals until approxi-
mately 3 months after surgery or screening, and then less
frequently for up to one year. The scores for EVAR and OR
incorporate complications, with the exception of the Ontario
study. In the Ontario study, the utility decrement due to
major complications, such as stroke, myocardial infarction,
congestive heart and renal failure was accounted for sepa-
rately, while other complications such as endoleaks were
included in the estimates. None of the studies reported
separate figures for complications, although the utility for
ruptured AAA after surgery was available.
The comparative utility of OR and EVAR varied consid-
erably between the Ontario, the DREAM and the EVAR1
studies, with the Ontario study being the most favorable for
EVAR. However the RCT-based evidence from the EVAR and
the DREAM trials might be regarded as a higher level than
that of the cohort study in the Ontario assessment report.
There is not a good explanation why there is such
a difference in the comparative utility results for EVAR
and OR between the 3 randomised trials as far as they are
comparable. Nevertheless, as utility results have a signifi-
cant influence on the cost-effectiveness assessment and
therefore on economic submissions to reimbursement
authorities, some issues should be taken into consideration.
The value of utility assessments in asymptomatic diseases is
less well recognized. In general a patient with an AAA is
asymptomatic and due to the nature of the intervention the
patient is expected to return to the pre-operative mental
and physical state in time. Complications will have an
effect on utility results.
Recent reports from patient registries suggest the
possibility of lower complication rates with endovascular
repair compared to the ones found by the EVAR and the
DREAM trials.30e32 This might be due to more experience
with the procedure, as recruitment for the EVAR trials
started in 1999, and for the DREAM trial in 2000. A different
attitude towards the frequent occurring Type II endoleaks
might lead to fewer re-interventions. Lower complication
and re-intervention rates would result in higher utilities.
Utility data in most cases are used in cost-utility
models calculating the incremental cost per quality-
adjusted life-year gained. These trials assist this task by
providing data reflecting the surgical experience and
complication rates at the time they were undertaken.
The assumption that complication rates remain the same,
even if more experience is gained with EVAR, seems to be
challenged by the recent registry results. The implications
of this could have been tested if the utilities in the trials
had been reported by different outcomes, such as success-
ful repair, conversion or the various types of complica-
tions. However this was outside the scope of both the
EVAR and the DREAM trials.
One of the limitations of the study was that it could not
take into account the differences in treatment patterns
between countries and in time regarding evaluation of the
fitness of patients, and the subsequent decision for eligi-
bility for EVAR. Similarly, the effect of varying the compli-
cations rates could not be estimated. This would require
a re-analysis of the utility data from the randomized trials
according the different clinical outcomes, to allow the
288 N. Muszbek et al.recalculation of utility results with different complication
and conversion rates.
Conclusion
There are very few studies calculating utilities in AAA. All
published studies were reported in clinical journals with
the main purpose of evaluating efficacy and safety, and not
to perform an economic analysis. Furthermore, the findings
of these studies are not consistent, and the limited and
varied reporting of these data prevents further analysis to
explain the differences.
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Appendix
The EQ-5D
The EQ-5D is a standardised utility instrument used to
measure health outcomes. It is applicable to a wide range
of health conditions and treatments, providing a simple
descriptive profile and a single index value for health
status, and is designed for self-completion by respondents
in the form of a straightforward questionnaire.
As part of the descriptive system, the EQ-5D contains five
health-related quality of life dimensions: 1) mobility, 2) self-
care, 3) usual activity, 4) pain/discomfort, and 5) anxiety/
depression. Each dimension is designated three levels
defining severity: a) ‘‘no problem’’, b) ‘‘some problem’’,
and c) ‘‘extreme problem’’. Subjects are asked to select the
categorymost descriptive of their current level of function or
experience for each dimension. Each category response for
the dimensions has a different level of negative weighted
score attached. The scores vary fromdimension to dimension
and the sum of these scores represents the final utility score.
Perfect health is represented by 1, and 0 represents death.
The classification system has been assigned several
different standardised scores derived through population-
based samples of respondents asked to assign values to
subsets of the 243 states. The most commonly used scoring
system is a ‘‘tariff’’ system of weights applied to thedimension levels (and an adjustment for interaction) de-
rived in the United Kingdom from a community sample of
persons.33 A set of valuation weights has been derived from
a U.S. sample more recently.34
The visual analogue scale (VAS) is often employed to
supplement the EQ-5D index. It measures the quality of life
with the help of a thermometer scale, where the current
health has to be placed between the two endpoints best
possible health and worst possible health. The VAS scores
are calculated using perfect health represented by 100, and
death represented by 0.
The Rosser Index. The Rosser Index classifies health states
along two dimensions. The eight levels of disability and the
four levels of distress allows for 32 different health states.
Thus it is less sensitive than the EQ-5D and the values for
each health state are derived from a small sample.35Conflict of Interest
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